Marizyme, Inc.
OTC: MRZM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David L. Barthel
- Employees
- 13
- Headquarters
- Jupiter, United States
- IPO year
- 2010
- Market cap
- $39.5K
- Website
- https://marizyme.com
Loading MRZM…
Loading profile data…Frequently asked questions about MRZM
What does Marizyme, Inc. (MRZM) do?
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critic...
Where does MRZM trade?
Marizyme, Inc. (MRZM) trades on the Other OTC.
What sector is MRZM in?
Marizyme, Inc. (MRZM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Marizyme, Inc.?
David L. Barthel is the chief executive officer of Marizyme, Inc. (MRZM).
Where is Marizyme, Inc. headquartered?
Marizyme, Inc. is headquartered in United States.
Does MRZM pay a dividend?
Marizyme, Inc. (MRZM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MRZM go public?
Marizyme, Inc. (MRZM) completed its initial public offering in 2010.